The effect of nutrition education interventions on dialysis patients' outcomes: a systematic review and meta-analysis.

Ann MedApr 22, 2026 (epub)
Clinical ResearchNephrologyOpen access

Sogand Sarmadi, Neda Sanaie, Akbar Zare-Kaseb

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the impact of nutrition education interventions on outcomes in adult dialysis patients. Analyzing 44 studies with 4,106 participants, the findings revealed significant improvements in knowledge (SMD = 1.09) and health-related quality of life (SMD = 1.43), along with modest reductions in serum potassium (SMD = -0.52) and phosphate (SMD = -0.35).

Key findings

  • Nutrition education improved knowledge with a standardized mean difference (SMD) of 1.09.
  • Health-related quality of life increased significantly with an SMD of 1.43.
  • Serum potassium levels decreased with an SMD of -0.52.
  • Serum phosphate levels were reduced with an SMD of -0.35.

Why it matters

Understanding the effectiveness of nutrition education can help clinicians develop strategies to enhance adherence to dietary restrictions in dialysis patients, potentially improving their clinical outcomes and quality of life.

What to keep in mind

Most outcomes were rated low or very low certainty due to inconsistency, indirectness, and imprecision.

Source

PubMed · PMID 42015790Free full text on PubMed Central

Published in Ann Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.